All newly approved drugs will default to non-preferred status until a full clinical review by the national pharmacy and therap

CIGNA Drug List Changes – Third Quarter 2009
CIGNA periodically reviews its drug list to promote continued effectiveness. Based on that review, the following
changes have been made to the CIGNA drug list from July 1, 2009 to September 30, 2009. Drugs marked with an (*), or (~) indicate that prior authorization, or step therapy is required, respectively. Note: This list includes selected brand and generic drug changes and is subject to change. CIGNA does not take responsibility for any medication decisions made by prescriber and pharmacist. Selected New Generic Drugs Added to Drug List
Reference Brand Name
Generic Name
__________________________________________________________________________________________ Benzaclin Fibricor~
Selected New Preferred Drugs Added to Drug List
Reference
__________________________________________________________________________________________
Analpram
Selected Non-Preferred Brands Switched to Preferred Brands
Brand Name
Generic Name
__________________________________________________________________________________________
* Prior Authorization
~Step Therapy
CIGNA Drug List Changes – Third Quarter 2009
Selected Preferred Brands Switched to Non-Preferred Brands
Brand Name
Generic Name
__________________________________________________________________________________________ chlorpheniramine/methscopolamine/phenylephrine phenylephrine/chlorpheniramine/methscopolamine guaifenesin/theophylline/pseudoephedrine Capital W/Codeine codeine/acetaminophen Colymycins S Cortisporin (ointment) neomycin/bacitracin/polymyxin/hydrocortisone Cortisporin (cream) neomycin/polymyxin/hydrocortisone chlorpheniramine/methscopolamine/phenylephrine Depo-Testosterone* testosterone cypionate phenylephrine/chlorpheniramine/methscopolamine Synalgos-DC dihydrocodeine/aspirin/caffeine Syprine CIGNA Drug List Changes – Third Quarter 2009
Selected Preferred Brands Switched to Non-Preferred Brands (continued)
Brand Name
Generic Name
__________________________________________________________________________________________ brompheniramine/dextromethorphan/guaifenesin Tusnel Pediatric guaifenesin/pseudoephedrine Tusnel Pediatric brompheniramine/dextromethorphan/guaifenesin Tyzine Brand Drugs at Highest Copay with other Brand / Generic Alternatives
Brand Name
Generic Name
__________________________________________________________________________________________ Selected New Brand Drugs Added as Non-Preferred Brands1
Brand Name
Generic Name
_________________________________________________________________________________________ Acuvail Adcirca*
Bepreve bepotastine
Edluar~
Embeda morphine/naltrexone
Fibricor~
Onglyza~
1All newly approved "priority" drugs and "non-priority" drugs as designated by the Food and Drug Administration ["FDA"]
will default to non-preferred status until review by the CIGNA Pharmacy and Therapeutics Committee (P&T Committee).
The P&T Committee reviews priority drugs within six months of FDA approval of the drug.

* Prior Authorization
~Step Therapy


CIGNA Drug List Changes – Third Quarter 2009

Removal of Step Therapy from Selected Drugs
Brand Name
Generic Name
____________________________________________________________________________________ Drug Recalls Removed from Drug List
Brand Name
Generic Name
____________________________________________________________________________________ CIGNA,” “CIGNA HealthCare,” “CIGNA Pharmacy Management” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, Tel-Drug, Inc. and its affiliates, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Source: http://www.centercare.com/whoweare/Drug_List_Changes_3Q2009.pdf

Microsoft word - study supports traditional diabetes therapy claim, email release.docx

Study supports traditional diabetes therapy claim A clinical trial by researchers at The University of Auckland’s Liggins Institute has shown that an extract of fresh olive leaves appreciably reduces some risk factors for developing type 2 diabetes. A paper published today in the peer-reviewed journal PLOS ONE presents results of the randomized, double-blinded, placebo-controlled, crossove

bordulot.fr

– Allez Edison, c’est l’heure ! Et pas de blagues cette fois, si tu mords encore les fesses de monsieur Pois pendant le cours, plus de Questions pour un Champion pendant un Edison partit se cacher sous le bureau de son maître avant même que celui-ci ait terminé sa phrase. Edison adorait la télé en général, et Julien Lepers en particulier. Fait rare chez un chien, certes, mai

© 2010-2018 PDF pharmacy articles